Purple Biotech Ltd Total Assets
Purple Biotech Ltd total assets. Based on the latest financial reports, Purple Biotech Ltd (KTOV) holds total assets worth ILA85.78 Million ILA (≈ $229.98K USD) as of June 2020. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Purple Biotech Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Purple Biotech Ltd (2009–2019)
Total assets of Purple Biotech Ltd from 2009 to 2019. This chart illustrates how Purple Biotech Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Purple Biotech Ltd for real-time trading data and today's change.
Purple Biotech Ltd - Asset Composition Analysis
Purple Biotech Ltd Total Assets Breakdown (December 2019)
Purple Biotech Ltd total assets breakdown as of December 2019. Purple Biotech Ltd's total assets of ILA85.78 Million consist of 56.4% current assets and 43.6% non-current assets. Explore working capital to net assets of Purple Biotech Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 29.8% |
| Accounts Receivable | ILA3.49 Million | 23.7% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA244.00K | 1.7% |
| Intangible Assets | ILA6.17 Million | 41.9% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2009–2019)
This chart illustrates how Purple Biotech Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Purple Biotech Ltd's current assets represent 56.4% of total assets in 2019, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 29.8% of total assets in 2019, up from 0.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, a decrease from 47.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 41.9% of total assets.
Purple Biotech Ltd Competitors by Total Assets
Key competitors of Purple Biotech Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩167.98 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
Purple Biotech Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 1.99 | 11.70 |
| Quick Ratio | 2.22 | 1.99 | 11.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA35.78 Million | ILA5.30 Million | ILA13.62 Million |
Purple Biotech Ltd - Advanced Valuation Insights
This section examines the relationship between Purple Biotech Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.27 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | ILA14.72 Million |
| Market Capitalization | $461.41K USD |
Valuation Analysis
Below Book Valuation: The market values Purple Biotech Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Purple Biotech Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Purple Biotech Ltd (2009–2019)
The table below shows the annual total assets of Purple Biotech Ltd from 2009 to 2019.
| Year | Total Assets | Change |
|---|---|---|
| 2019-12-31 | ILA14.72 Million ≈ $39.46K |
-0.03% |
| 2018-12-31 | ILA14.72 Million ≈ $39.47K |
+3.81% |
| 2017-12-31 | ILA14.18 Million ≈ $38.02K |
-4.90% |
| 2016-12-31 | ILA14.91 Million ≈ $39.98K |
+37.94% |
| 2015-12-31 | ILA10.81 Million ≈ $28.99K |
+514.67% |
| 2014-12-31 | ILA1.76 Million ≈ $4.72K |
+465.59% |
| 2013-12-31 | ILA311.00K ≈ $833.78 |
-95.92% |
| 2011-12-31 | ILA7.62 Million ≈ $20.42K |
-19.65% |
| 2010-12-31 | ILA9.48 Million ≈ $25.41K |
-28.45% |
| 2009-12-31 | ILA13.25 Million ≈ $35.52K |
-- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more